Geopolitical uncertainty, tariff risk, and the UK’s 10-Year Life Sciences Plan are simultaneously reshaping
where British pharma and medtech companies manufacture.
The UK government unveiled its 10-Year Life Sciences Plan in July 2025, aiming to fix a long-acknowledged gap between the UK’s strengths in discovery and its weaknesses in commercialisation and manufacturing scale-up. The plan explicitly targets foreign direct investment in life sciences manufacturing and frames NHS reforms as part of the same commercial proposition. In the same month, the US-UK Technology Prosperity Deal saw Prologis commit $5.13 billion in investment to UK science infrastructure including the Cambridge Biomedical Campus.
The backdrop to this investment push is a supply chain restructuring that is already underway. Geopolitical
uncertainty, biosecurity concerns, tariff risk, and regulatory divergence are directly shaping manufacturing choices for UK life sciences companies. The Critical Imports and Supply Chains Strategy, launched in 2024, reflects government recognition that pandemic-era vulnerabilities have not been adequately addressed. Life sciences is identified as a priority sector for domestic manufacturing resilience.
For UK companies, the restructuring is creating active location decisions rather than strategic reviews. The 2026 life sciences executive outlook from Deloitte identifies supply chain risk and geopolitical shifts as top factors shaping corporate strategy this year, with 38% of executives citing these explicitly. Companies are evaluating where to add production capacity that is geographically diversified, regulatory-credible, and commercially proximate to key markets – criteria that go well beyond the traditional cost-minimisation framework.
The destinations best placed to benefit are those that can offer a combination of regulatory alignment with UK and EU standards, skilled manufacturing talent, developed life sciences infrastructure, and established commercial relationships with British companies. This is not a generic proposition – it is sector-specific, and the companies making these decisions will evaluate it with precision.
The UK life sciences supply chain restructuring is producing investment decisions that will be visible over the next 24 to 36 months. The destinations engaged in the conversation now will have a meaningful advantage over those responding to announcements.
Nueconomy operates directly in the UK and tracks expansion intent among British life sciences companies through CUE.
If you are a destination market positioning for UK life sciences manufacturing investment, we can help you identify the right companies and build the right case.
hello@nueconomy.co · thenueconomy.com
Related: UK Manufacturers Are Rerouting
